PubMed:32266987 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":0,"end":14},"obj":"CHEBI:50858"},{"id":"T2","span":{"begin":0,"end":14},"obj":"CHEBI:50858"},{"id":"T3","span":{"begin":42,"end":53},"obj":"NCBITaxon:11118"},{"id":"T4","span":{"begin":68,"end":76},"obj":"SP_7"},{"id":"T5","span":{"begin":117,"end":131},"obj":"CHEBI:50858"},{"id":"T6","span":{"begin":117,"end":131},"obj":"CHEBI:50858"},{"id":"T7","span":{"begin":159,"end":170},"obj":"NCBITaxon:11118"},{"id":"T8","span":{"begin":185,"end":193},"obj":"SP_7"},{"id":"T9","span":{"begin":244,"end":252},"obj":"SP_7"},{"id":"T10","span":{"begin":402,"end":413},"obj":"UBERON:0001004"},{"id":"T11","span":{"begin":414,"end":425},"obj":"NCBITaxon:11118"},{"id":"T12","span":{"begin":429,"end":439},"obj":"SP_7"},{"id":"T13","span":{"begin":624,"end":638},"obj":"CHEBI:50858"},{"id":"T14","span":{"begin":624,"end":638},"obj":"CHEBI:50858"},{"id":"T15","span":{"begin":685,"end":693},"obj":"SP_7"},{"id":"T16","span":{"begin":703,"end":717},"obj":"CHEBI:50858"},{"id":"T17","span":{"begin":703,"end":717},"obj":"CHEBI:50858"},{"id":"T18","span":{"begin":807,"end":821},"obj":"CHEBI:50858"},{"id":"T19","span":{"begin":807,"end":821},"obj":"CHEBI:50858"},{"id":"T20","span":{"begin":836,"end":841},"obj":"NCBITaxon:10239"},{"id":"T21","span":{"begin":1048,"end":1053},"obj":"NCBITaxon:10239"},{"id":"T22","span":{"begin":1193,"end":1208},"obj":"CHEBI:50858"},{"id":"T23","span":{"begin":1193,"end":1208},"obj":"CHEBI:50858"},{"id":"T24","span":{"begin":1253,"end":1261},"obj":"SP_7"},{"id":"T25","span":{"begin":1346,"end":1357},"obj":"UBERON:0001004"},{"id":"T26","span":{"begin":1389,"end":1392},"obj":"NCBITaxon:10376"},{"id":"T27","span":{"begin":1413,"end":1423},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).\nOBJECTIVES: To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).\nDESIGN, SETTING: Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020.\nPARTICIPANTS: Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals.\nMAIN OUTCOME MEASURES: Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy).\nRESULTS: Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days).\nCONCLUSIONS: Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated."}